MCID: THY023
MIFTS: 64

Thymoma

Categories: Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Thymoma

Summaries for Thymoma

Disease Ontology : 12 A thymus cancer that derives from epithelial cells located in the thymus. The tumor cells in a thymoma look similar to the normal cells of the thymus, grow slowly, and rarely spread beyond the thymus.

MalaCards based summary : Thymoma, also known as thymus neoplasms, is related to thymic carcinoma and type c thymoma. An important gene associated with Thymoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Activation of cAMP-Dependent PKA and Developmental Biology. The drugs Antimitotic Agents and Tubulin Modulators have been mentioned in the context of this disorder. Affiliated tissues include thymus, t cells and bone marrow, and related phenotypes are neoplasm of the thymus and abnormality of the mediastinum

Wikipedia : 73 A thymoma is a tumor originating from the epithelial cells of the thymus that is considered a rare... more...

Related Diseases for Thymoma

Diseases in the Thymoma family:

Thymoma, Familial Invasive Malignant Thymoma
Type C Thymoma Malignant Type Ab Thymoma
Malignant Type a Thymoma Thymoma Type a
Thymoma Type B Thymoma Type Ab

Diseases related to Thymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 757)
# Related Disease Score Top Affiliating Genes
1 thymic carcinoma 32.8 NKX2-1 KIT CD5
2 type c thymoma 32.6 KIT CD5
3 myasthenia gravis 32.5 TTN RYR1 IL2 CTLA4 AIRE
4 dendritic cell thymoma 32.4 TTN CD5 AIRE
5 epithelial malignant thymoma 32.3 TTN LCK CD5 AIRE
6 thymic epithelial tumor 32.1 KIT CD5
7 thymus cancer 31.5 TTN PTPRC NKX2-1 LCK KIT IL2
8 thyroiditis 31.1 IL2 CTLA4 AIRE
9 lymphoblastic lymphoma 30.7 PTPRC DNTT CD5
10 immune deficiency disease 30.7 PTPRC LCK IL2 CTLA4 CD5 AKT1
11 mediastinal cancer 30.6 PTPRC NKX2-1 KIT CD5
12 pemphigus foliaceus 30.6 PPL EVPL CTLA4
13 ectopic thymus 30.6 NKX2-1 CD5
14 hashimoto thyroiditis 30.6 HRAS CTLA4 AKT1 AIRE
15 skin disease 30.5 KIT IL2 HRAS CTLA4 AKT1
16 vitiligo-associated multiple autoimmune disease susceptibility 1 30.5 IL2 CTLA4 AIRE
17 t-cell lymphoblastic leukemia/lymphoma 30.4 PTPRC LCK IL2 AKT1
18 combined immunodeficiency 30.3 PTPRC LCK KIT IL2 CTLA4 AKT1
19 lymphoepithelioma-like thymic carcinoma 30.3 KIT CD5
20 alopecia areata 30.3 IL2 CTLA4 AIRE
21 neuroendocrine carcinoma 30.3 PTPRC NKX2-1 KIT
22 severe combined immunodeficiency 30.3 PTPRC LCK KIT IL2
23 mast cell neoplasm 30.2 KIT IL2 CTLA4
24 small cell cancer of the lung 30.2 PTPRC NKX2-1 KIT AKT1
25 small cell carcinoma 30.2 PTPRC NKX2-1 KIT
26 lymphoproliferative syndrome 30.2 PTPRC IL2 CTLA4 CD5
27 peripheral nervous system disease 30.2 RYR1 PTPRC KIT IL2 HRAS DPYSL5
28 lymphoma, non-hodgkin, familial 30.0 PTPRC LCK IL2 DNTT CD5 AKT1
29 t cell deficiency 30.0 PTPRC IL2 CTLA4
30 iga pemphigus 29.9 PPL EVPL
31 follicular dendritic cell sarcoma 29.9 PPL KIT EVPL
32 gastric adenocarcinoma 29.9 LRRC56 KIT HRAS AKT1
33 gliosarcoma 29.9 LRRC56 IL2 HRAS AKT1
34 nevus, epidermal 29.9 LRRC56 HRAS AKT3 AKT2 AKT1
35 t-cell acute lymphoblastic leukemia 29.9 PTPRC LCK IL2 DNTT CTLA4 AKT1
36 exanthem 29.9 KIT IL2 HRAS CTLA4 AKT1
37 lung squamous cell carcinoma 29.8 TTN LRRC56 HRAS AKT1
38 thyroid gland follicular carcinoma 29.8 NKX2-1 LRRC56 KIT HRAS AKT1
39 melanoma 29.8 LRRC56 KIT IL2 HRAS CTLA4 AKT3
40 skin carcinoma 29.8 PTPRC NKX2-1 LRRC56 KIT IL2 HRAS
41 leukemia, chronic lymphocytic 29.8 PTPRC LRRC56 LCK IL2 HRAS DNTT
42 rhabdomyosarcoma 29.7 TTN PTPRC LRRC56 KIT HRAS AKT1
43 myelodysplastic syndrome 29.6 LRRC56 KIT IL2 HRAS DNTT AKT1
44 leukemia, acute lymphoblastic 29.6 PTPRC LCK KIT IL2 HRAS EVPL
45 myeloma, multiple 29.5 PTPRC NKX2-1 LRRC56 KIT IL2 HRAS
46 leukemia, acute myeloid 28.9 PTPRC LRRC56 LCK KIT IL2 HRAS
47 thymoma, familial 11.7
48 good syndrome 11.5
49 spindle cell thymoma 11.3
50 cortical thymoma 11.3

Graphical network of the top 20 diseases related to Thymoma:



Diseases related to Thymoma

Symptoms & Phenotypes for Thymoma

Human phenotypes related to Thymoma:

31 (show all 29)
# Description HPO Frequency HPO Source Accession
1 neoplasm of the thymus 31 hallmark (90%) HP:0100521
2 abnormality of the mediastinum 31 hallmark (90%) HP:0045026
3 ptosis 31 frequent (33%) HP:0000508
4 diplopia 31 frequent (33%) HP:0000651
5 dysphagia 31 frequent (33%) HP:0002015
6 fatigue 31 frequent (33%) HP:0012378
7 dyspnea 31 frequent (33%) HP:0002094
8 cough 31 frequent (33%) HP:0012735
9 chest pain 31 frequent (33%) HP:0100749
10 lymphadenopathy 31 frequent (33%) HP:0002716
11 fatigable weakness 31 frequent (33%) HP:0003473
12 abnormal pulmonary interstitial morphology 31 frequent (33%) HP:0006530
13 arthritis 31 occasional (7.5%) HP:0001369
14 alopecia 31 occasional (7.5%) HP:0001596
15 thyroiditis 31 occasional (7.5%) HP:0100646
16 hemolytic anemia 31 occasional (7.5%) HP:0001878
17 nephrotic syndrome 31 occasional (7.5%) HP:0000100
18 pericarditis 31 occasional (7.5%) HP:0001701
19 myocarditis 31 occasional (7.5%) HP:0012819
20 skin rash 31 occasional (7.5%) HP:0000988
21 limitation of joint mobility 31 occasional (7.5%) HP:0001376
22 keratoconjunctivitis sicca 31 occasional (7.5%) HP:0001097
23 abnormality of the peritoneum 31 occasional (7.5%) HP:0002585
24 pancytopenia 31 occasional (7.5%) HP:0001876
25 myositis 31 occasional (7.5%) HP:0100614
26 xerostomia 31 occasional (7.5%) HP:0000217
27 b lymphocytopenia 31 occasional (7.5%) HP:0010976
28 decreased circulating antibody level 31 occasional (7.5%) HP:0004313
29 abnormal pleura morphology 31 occasional (7.5%) HP:0002103

GenomeRNAi Phenotypes related to Thymoma according to GeneCards Suite gene sharing:

26 (show all 42)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.88 HRAS
2 Decreased viability GR00055-A-2 10.88 HRAS
3 Decreased viability GR00055-A-3 10.88 LCK
4 Decreased viability GR00221-A-1 10.88 AKT1 AKT3 HRAS LCK AKT2 KIT
5 Decreased viability GR00221-A-2 10.88 AKT1 AKT3 HRAS LCK TTN
6 Decreased viability GR00221-A-3 10.88 AKT1 AKT3 HRAS LCK AKT2
7 Decreased viability GR00221-A-4 10.88 AKT1 AKT3 TTN AKT2
8 Decreased viability GR00249-S 10.88 AKT1
9 Decreased viability GR00301-A 10.88 AKT3 LCK AKT2 KIT
10 Decreased viability GR00342-S-1 10.88 LCK TTN
11 Decreased viability GR00342-S-3 10.88 LCK TTN AKT2
12 Decreased viability GR00386-A-1 10.88 LCK
13 Increased shRNA abundance (Z-score > 2) GR00366-A-110 10.13 AKT2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.13 AKT3
15 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.13 LCK
16 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.13 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.13 KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.13 AKT2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.13 AKT3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.13 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.13 AIRE
22 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.13 LCK
23 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.13 AKT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.13 AIRE AKT2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.13 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.13 AKT2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.13 AKT3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.13 AKT1 AKT2 AKT3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-61 10.13 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.13 AKT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-80 10.13 AIRE
32 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.13 AKT1 AKT2 AKT3 KIT LCK
33 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.13 KIT
34 Increased shRNA abundance (Z-score > 2) GR00366-A-98 10.13 LCK
35 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.13 KIT
36 Decreased substrate adherent cell growth GR00193-A-1 10 AKT2 KIT
37 Decreased substrate adherent cell growth GR00193-A-2 10 AKT2 AKT3 KIT LCK
38 Decreased substrate adherent cell growth GR00193-A-3 10 AKT2 AKT3 LCK
39 Decreased substrate adherent cell growth GR00193-A-4 10 KIT LCK
40 Decreased cell migration GR00055-A-1 9.72 AKT1 AKT2 AKT3 LCK
41 Decreased cell migration GR00055-A-3 9.72 HRAS
42 Increased transferrin (TF) endocytosis (mild increase), increased transferrin (TF) endosome elongation GR00363-A 8.32 HRAS

MGI Mouse Phenotypes related to Thymoma:

46 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 AIRE AKT1 AKT2 AKT3 CTLA4 DNTT
2 growth/size/body region MP:0005378 10.29 AIRE AKT1 AKT2 AKT3 CD5 DNTT
3 hematopoietic system MP:0005397 10.27 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
4 immune system MP:0005387 10.25 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
5 endocrine/exocrine gland MP:0005379 10.24 AIRE AKT1 AKT2 AKT3 CTLA4 HRAS
6 digestive/alimentary MP:0005381 10.11 AIRE CTLA4 HRAS IL2 KIT NKX2-1
7 integument MP:0010771 10.07 AKT1 AKT2 CD5 CTLA4 EVPL HRAS
8 neoplasm MP:0002006 9.97 AIRE AKT1 AKT2 AKT3 HRAS IL2
9 normal MP:0002873 9.97 AIRE AKT1 AKT2 AKT3 CD5 CTLA4
10 no phenotypic analysis MP:0003012 9.86 AIRE AKT2 CD5 HRAS IL2 KIT
11 respiratory system MP:0005388 9.65 AIRE AKT1 AKT2 CTLA4 HRAS IL2
12 skeleton MP:0005390 9.32 AKT1 AKT2 CTLA4 DNTT HRAS KIT

Drugs & Therapeutics for Thymoma

Drugs for Thymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 134)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antimitotic Agents Phase 4
2 Tubulin Modulators Phase 4
3
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
5
Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
6
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
7
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
8
Etoposide Approved Phase 3 33419-42-0 36462
9
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
10 Methylprednisolone Acetate Phase 3
11 Etoposide phosphate Phase 3
12
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5005498 5330286
13
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
14
Pasireotide Approved Phase 2 396091-73-9 9941444
15
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
16
Melphalan Approved Phase 2 148-82-3 4053 460612
17
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
18
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
19
Busulfan Approved, Investigational Phase 2 55-98-1 2478
20
ramucirumab Approved, Investigational Phase 2 947687-13-0
21
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
22
Nedaplatin Approved, Investigational Phase 2 95734-82-0
23
nivolumab Approved Phase 2 946414-94-4
24
Plicamycin Approved, Investigational, Withdrawn Phase 1, Phase 2 18378-89-7 163659 163660 163661 163662 163663 163664
25
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
26
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
27
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
28
Lapatinib Approved, Investigational Phase 2 231277-92-2, 388082-78-8 208908 9941095
29
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
30
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
31
Pembrolizumab Approved Phase 2 1374853-91-4
32
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
33
Povidone Approved Phase 1, Phase 2 9003-39-8 131751496
34
Povidone-iodine Approved Phase 1, Phase 2 25655-41-8
35
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
36
Lenvatinib Approved, Investigational Phase 2 417716-92-8
37
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
38
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
39
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
40
Belinostat Approved, Investigational Phase 1, Phase 2 866323-14-0
41
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
42
Histamine Approved, Investigational Phase 2 51-45-6, 75614-87-8 774
43
Doxepin Approved, Investigational Phase 2 1668-19-5 667477 667468
44
Promethazine Approved, Investigational Phase 2 60-87-7 4927
45
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
46
Amrubicin Investigational Phase 2 110267-81-7
47
Lexatumumab Investigational Phase 2 845816-02-6
48
Molgramostim Investigational Phase 2 99283-10-0
49
Cadexomer iodine Experimental Phase 1, Phase 2 94820-09-4
50
Saracatinib Investigational Phase 2 379231-04-6

Interventional clinical trials:

(show top 50) (show all 102)
# Name Status NCT ID Phase Drugs
1 Single-Arm Study to Carbo-paclitaxel/ Nab-paclitaxel Combined With Pembrolizumab as the First Line Therapy in Treating Patients With Locally Advanced or Metastatic Invasive Thymoma and Thymic Carcinoma That Cannot Be Removed by Surgery Recruiting NCT04554524 Phase 4 Chemotherapy+Pembrolizumab.
2 A Multi-Center, Single-Blind, Randomized Study Comparing Thymectomy to No Thymectomy in Non-Thymomatous Myasthenia Gravis (MG) Patients Receiving Prednisone Completed NCT00294658 Phase 3 prednisone alone
3 An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection Recruiting NCT02633553 Phase 3
4 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
5 A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma Recruiting NCT02014805 Phase 3
6 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Unknown status NCT03449173 Phase 2 Sunitinib
7 A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Unknown status NCT03466827 Phase 2 Selinexor
8 Samsung Medical Center Unknown status NCT03219554 Phase 2 Palbociclib
9 Efficacy of Medical Treatment With Octreotide in Patients With Primary Inoperable Thymoma to Reduce Tumor Size Completed NCT00332969 Phase 2 Octreotide
10 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
11 Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size Completed NCT02021942 Phase 2 SOM230 LAR
12 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
13 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
14 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
15 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
16 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
17 Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Completed NCT02049047 Phase 2 Everolimus
18 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
19 A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
20 A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin Completed NCT02420691 Phase 2 Ribociclib
21 Radiofrequency Ablation of Pulmonary Malignancy Completed NCT00024076 Phase 2
22 A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy Completed NCT02607631 Phase 2 Pembrolizumab
23 A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
24 Efficacy and Safety of High Dose Regimen of Octreotide LAR in Patients With Neuroendocrine Tumors in Progressive Disease: A Phase II, Open, Multicentric Prospective Study Completed NCT00990535 Phase 2 Octreotide-LAR
25 Surgical Cytoreduction Followed by Intraoperative Intrathoracic Hyperthermic Chemotherapy Perfusion for the Management of Disseminated Pleural Malignancies Completed NCT01163552 Phase 2
26 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
27 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
28 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Recruiting NCT03921671 Phase 2
29 A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Recruiting NCT04417660 Phase 2 M7824
30 A Prospective, Phase Ⅱ Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
31 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
32 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
33 A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT) Recruiting NCT03193437 Phase 2 Open Label Selinexor
34 Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases Recruiting NCT02859415 Phase 1, Phase 2 Mithramycin
35 A Phase II, Neo-adjuvant Pembrolizumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Pembrolizumab Consolidation Therapy in Locally Advanced Thymic Epithelial Tumor (TET) Recruiting NCT03858582 Phase 2 pembrolizumab
36 A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
37 A Phase 2, Open-Label, Multi-Center Study to Evaluate Efficacy, Safety and Tolerability of KN046 in Subjects With Thymic Carcinoma Recruiting NCT04469725 Phase 2 KN046
38 An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma Recruiting NCT04321330 Phase 2 Atezolizumab
39 A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma Recruiting NCT03463460 Phase 2 Sunitinib Malate
40 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
41 A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy Active, not recruiting NCT01621568 Phase 2 Sunitinib
42 A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007) Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
43 Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
44 An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Active, not recruiting NCT02307500 Phase 2 Regorafenib
45 Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Active, not recruiting NCT01306045 Phase 2 AZD6244;MK-2206;Lapatinib;Erlotinib;Sunitinib
46 Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors Not yet recruiting NCT04517539 Phase 2 rhGM-CSF,Peginterferon alfa-b2,radiation
47 Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor Not yet recruiting NCT04667793 Phase 2 Toripalimab;Chemotherapy;Chemotherapy
48 The Study of Extended Thymectomy and Pleural Reductive Surgery (PRS) With Povidone-iodine Pleural Lavage in Patients With Stage IVA Thymic Malignancies Not yet recruiting NCT04371458 Phase 1, Phase 2 Intraoperative providone-iodine lavage
49 A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic Carcinoma PaTIents. PECATI. Not yet recruiting NCT04710628 Phase 2 Pembrolizumab;Lenvatinib 10 mg
50 A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas Suspended NCT02220855 Phase 2 BKM120

Search NIH Clinical Center for Thymoma

Cochrane evidence based reviews: thymoma

Genetic Tests for Thymoma

Anatomical Context for Thymoma

The Foundational Model of Anatomy Ontology organs/tissues related to Thymoma:

19
Thymus

MalaCards organs/tissues related to Thymoma:

40
Thymus, T Cells, Bone Marrow, Thyroid, Lung, B Cells, Myeloid

Publications for Thymoma

Articles related to Thymoma:

(show top 50) (show all 8287)
# Title Authors PMID Year
1
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. 6 61
19861435 2009
2
Mutational status of EGFR and KIT in thymoma and thymic carcinoma. 6 61
18448188 2008
3
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
4
When a thymic carcinoma "becomes" a GIST. 6
23375402 2013
5
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 6
22357254 2012
6
Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. 6
21969494 2011
7
Large-scale analysis of KIT aberrations in Chinese patients with melanoma. 6
21325067 2011
8
Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation. 6
20970876 2011
9
Thymic tumors: relevant molecular data in the clinic. 6
20859122 2010
10
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. 6
20736294 2010
11
Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. 6
19461405 2009
12
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. 6
17699867 2007
13
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. 6
17372901 2007
14
Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. 6
15930355 2005
15
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. 6
15201427 2004
16
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. 6
12960119 2003
17
Phosphatidylinositol 4,5-bisphosphate-specific AKT1 is oncogenic. 54 61
19876913 2010
18
Serotonin 1A receptor gene is associated with Japanese methamphetamine-induced psychosis patients. 54 61
19747927 2010
19
The PTPN22gain-of-function+1858T(+) genotypes correlate with low IL-2 expression in thymomas and predispose to myasthenia gravis. 61 54
19693092 2009
20
Lack of association between AKT1 variances versus clinical manifestations and social function in patients with schizophrenia. 61 54
18635704 2009
21
AKT1 Gene Polymorphisms and Obstetric Complications in the Patients with Schizophrenia. 61 54
20046382 2009
22
Spiradenoma reminiscent of thymoma: report of a case and review of the literature. 61 54
18647207 2009
23
Early loss of mammalian target of rapamycin complex 1 (mTORC1) signalling and reduction in cell size during dominant-negative suppression of hepatic nuclear factor 1-alpha (HNF1A) function in INS-1 insulinoma cells. 61 54
18949455 2009
24
Autoantibodies against type I interferons as an additional diagnostic criterion for autoimmune polyendocrine syndrome type I. 61 54
18728167 2008
25
Protein phosphatase 3 differentially modulates vascular endothelial growth factor- and fibroblast growth factor 2-stimulated cell proliferation and signaling in ovine fetoplacental artery endothelial cells. 61 54
18509162 2008
26
Infrequent and low AIRE expression in thymoma: difference in AIRE expression among WHO subtypes does not correlate with association of MG. 54 61
18568643 2008
27
CRMP5 antibodies in patients with small-cell lung cancer or thymoma. 61 54
17657489 2008
28
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. 61 54
18567864 2008
29
Graft-versus-host-like disease complicating thymoma: lack of AIRE expression as a cause of non-hereditary autoimmunity? 61 54
17928069 2007
30
Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. 61 54
17590173 2007
31
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. 54 61
17611497 2007
32
Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. 61 54
17539937 2007
33
Is excitation-contraction coupling impaired in myasthenia gravis? 54 61
17307394 2007
34
Deficiency of the autoimmune regulator AIRE in thymomas is insufficient to elicit autoimmune polyendocrinopathy syndrome type 1 (APS-1). 54 61
17334980 2007
35
Expression of p63 in thymomas and normal thymus. 61 54
17276940 2007
36
AKT1 and neurocognition in schizophrenia. 54 61
17464696 2007
37
[Thymus CT scan and thymoma associated antibodies in myasthenia gravis with thymoma]. 54 61
16995304 2006
38
Exogenous nitric oxide stimulates cell proliferation via activation of a mitogen-activated protein kinase pathway in ovine fetoplacental artery endothelial cells. 54 61
16251502 2006
39
Titin and ryanodine receptor antibodies in myasthenia gravis. 54 61
16637922 2006
40
[Correlation between MMP-2 activation and MT1-MMP mRNA expression in thymic epithelial tumors]. 61 54
16608644 2006
41
Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. 54 61
16125946 2005
42
Autoantibody production from a thymoma and a follicular dendritic cell sarcoma associated with paraneoplastic pemphigus. 61 54
16120143 2005
43
Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines. 61 54
15760917 2005
44
Analysis of cell cycle regulator proteins in encapsulated thymomas. 61 54
16033820 2005
45
[Expression of the p56lck by colon tumors: a marker of their invasive capacity?]. 61 54
15634634 2004
46
Association of AKT1 with schizophrenia confirmed in a Japanese population. 61 54
15522255 2004
47
The significance of titin antibodies in myasthenia gravis--correlation with thymoma and severity of myasthenia gravis. 61 54
15316806 2004
48
Expression of cyclins D1, D3 and p27 in thymic epithelial tumors. 61 54
17670226 2004
49
Hematopoietic progenitor cells as possible origins of epithelial thymoma in a human T lymphocyte virus type I pX gene transgenic rat model. 61 54
14688799 2004
50
Paraneoplastic movement disorder in a patient with non-Hodgkin's lymphoma and CRMP-5 autoantibody. 54 61
14673901 2003

Variations for Thymoma

ClinVar genetic disease variations for Thymoma:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KIT NM_000222.2(KIT):c.1468G>A (p.Glu490Lys) SNV Pathogenic 375903 rs1057519701 GRCh37: 4:55592144-55592144
GRCh38: 4:54725978-54725978
2 KIT NM_001093772.1(KIT):c.1664_1666TTG[1] (p.Val556del) Microsatellite Pathogenic 375913 rs121913685 GRCh37: 4:55593609-55593611
GRCh38: 4:54727443-54727445
3 KIT NM_000222.2(KIT):c.1730_1738del (p.Pro577_Asp579del) Deletion Pathogenic 375920 rs1131692239 GRCh37: 4:55593662-55593670
GRCh38: 4:54727496-54727504
4 KIT NM_000222.2(KIT):c.1657T>A (p.Tyr553Asn) SNV Pathogenic 375907 rs1057519704 GRCh37: 4:55593591-55593591
GRCh38: 4:54727425-54727425
5 KIT NM_000222.2(KIT):c.2460T>A (p.Asp820Glu) SNV Pathogenic 375929 rs1057519711 GRCh37: 4:55599334-55599334
GRCh38: 4:54733168-54733168
6 KIT NM_000222.2(KIT):c.1676T>C (p.Val559Ala) SNV Pathogenic 13865 rs121913517 GRCh37: 4:55593610-55593610
GRCh38: 4:54727444-54727444
7 KIT NM_000222.2(KIT):c.1669T>C (p.Trp557Arg) SNV Pathogenic 375909 rs121913235 GRCh37: 4:55593603-55593603
GRCh38: 4:54727437-54727437
8 KIT NM_000222.2(KIT):c.2089C>T (p.His697Tyr) SNV Pathogenic 375925 rs763308199 GRCh37: 4:55595599-55595599
GRCh38: 4:54729433-54729433
9 KIT NM_000222.2(KIT):c.1727T>C (p.Leu576Pro) SNV Pathogenic 375919 rs121913513 GRCh37: 4:55593661-55593661
GRCh38: 4:54727495-54727495
10 HRAS , LRRC56 NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Likely pathogenic 180848 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285

Expression for Thymoma

Search GEO for disease gene expression data for Thymoma.

Pathways for Thymoma

Pathways related to Thymoma according to GeneCards Suite gene sharing:

(show top 50) (show all 115)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.64 RYR1 PTPRC KIT IL2 HRAS AKT3
2
Show member pathways
13.49 PTPRC PPL KIT IL2 HRAS EVPL
3
Show member pathways
13.48 LCK KIT IL2 HRAS AKT3 AKT2
4
Show member pathways
13.47 PTPRC PPL LCK KIT HRAS CTLA4
5
Show member pathways
13.39 TTN LCK IL2 HRAS AKT3 AKT2
6
Show member pathways
13.37 PTPRC KIT IL2 HRAS AKT3 AKT2
7
Show member pathways
13.11 LCK KIT IL2 HRAS AKT3 AKT2
8
Show member pathways
13.06 KIT IL2 HRAS AKT3 AKT2 AKT1
9
Show member pathways
12.91 KIT HRAS AKT3 AKT2 AKT1
10 12.9 KIT IL2 HRAS AKT3 AKT2 AKT1
11
Show member pathways
12.85 IL2 HRAS AKT3 AKT2 AKT1
12 12.84 KIT HRAS AKT3 AKT2 AKT1
13
Show member pathways
12.84 KIT HRAS AKT3 AKT2 AKT1
14
Show member pathways
12.82 PTPRC LCK IL2 HRAS AKT3 AKT2
15
Show member pathways
12.81 PTPRC HRAS AKT3 AKT2 AKT1
16
Show member pathways
12.81 KIT HRAS AKT3 AKT2 AKT1
17
Show member pathways
12.79 RYR1 HRAS AKT3 AKT2 AKT1
18
Show member pathways
12.76 LCK KIT HRAS AKT3 AKT2 AKT1
19
Show member pathways
12.73 LCK HRAS AKT3 AKT2 AKT1
20
Show member pathways
12.66 IL2 HRAS AKT3 AKT2 AKT1
21
Show member pathways
12.65 PTPRC HRAS AKT3 AKT2 AKT1
22
Show member pathways
12.65 PTPRC LCK HRAS CTLA4 AKT3 AKT2
23 12.63 PTPRC LCK KIT IL2 CTLA4
24
Show member pathways
12.63 NKX2-1 HRAS AKT3 AKT2 AKT1
25
Show member pathways
12.6 LCK CTLA4 AKT3 AKT2 AKT1
26
Show member pathways
12.6 PTPRC LCK IL2 HRAS AKT3 AKT2
27
Show member pathways
12.59 PTPRC LCK HRAS AKT3 AKT2 AKT1
28
Show member pathways
12.49 IL2 HRAS AKT3 AKT2 AKT1
29
Show member pathways
12.47 HRAS AKT3 AKT2 AKT1
30
Show member pathways
12.47 HRAS AKT3 AKT2 AKT1
31
Show member pathways
12.47 HRAS AKT3 AKT2 AKT1
32
Show member pathways
12.46 IL2 HRAS AKT3 AKT2 AKT1
33
Show member pathways
12.45 KIT HRAS AKT3 AKT2 AKT1
34
Show member pathways
12.45 PTPRC LCK HRAS AKT3 AKT2 AKT1
35
Show member pathways
12.42 HRAS AKT3 AKT2 AKT1
36
Show member pathways
12.42 HRAS AKT3 AKT2 AKT1
37
Show member pathways
12.41 PTPRC LCK HRAS AKT3 AKT2 AKT1
38
Show member pathways
12.4 HRAS AKT3 AKT2 AKT1
39
Show member pathways
12.39 HRAS AKT3 AKT2 AKT1
40
Show member pathways
12.39 HRAS AKT3 AKT2 AKT1
41
Show member pathways
12.39 HRAS AKT3 AKT2 AKT1
42
Show member pathways
12.39 HRAS AKT3 AKT2 AKT1
43
Show member pathways
12.38 HRAS AKT3 AKT2 AKT1
44 12.37 HRAS AKT3 AKT2 AKT1
45
Show member pathways
12.3 HRAS AKT3 AKT2 AKT1
46
Show member pathways
12.3 PTPRC LCK IL2 HRAS CTLA4 AKT3
47 12.29 LCK IL2 HRAS AKT3 AKT2 AKT1
48
Show member pathways
12.27 HRAS AKT3 AKT2 AKT1
49 12.26 HRAS AKT3 AKT2 AKT1
50
Show member pathways
12.25 HRAS AKT3 AKT2 AKT1

GO Terms for Thymoma

Biological processes related to Thymoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 KIT IL2 HRAS AKT2 AKT1
2 positive regulation of gene expression GO:0010628 9.93 TTN NKX2-1 KIT HRAS AKT1
3 phosphorylation GO:0016310 9.88 TTN LCK KIT AKT3 AKT2 AKT1
4 protein phosphorylation GO:0006468 9.8 TTN LCK KIT AKT3 AKT2 AKT1
5 positive regulation of protein phosphorylation GO:0001934 9.73 IL2 HRAS AKT2 AKT1
6 T cell receptor signaling pathway GO:0050852 9.67 PTPRC LCK HRAS CTLA4
7 positive regulation of phospholipase C activity GO:0010863 9.56 KIT HRAS
8 mammary gland epithelial cell differentiation GO:0060644 9.55 AKT2 AKT1
9 negative thymic T cell selection GO:0045060 9.52 PTPRC AIRE
10 positive regulation of mitochondrial membrane potential GO:0010918 9.51 AKT2 AKT1
11 positive regulation of glucose metabolic process GO:0010907 9.49 AKT2 AKT1
12 positive regulation of isotype switching to IgG isotypes GO:0048304 9.48 PTPRC IL2
13 peripheral nervous system myelin maintenance GO:0032287 9.46 AKT2 AKT1
14 release of sequestered calcium ion into cytosol GO:0051209 9.33 RYR1 PTPRC LCK
15 negative regulation of plasma membrane long-chain fatty acid transport GO:0010748 9.26 AKT2 AKT1
16 T cell costimulation GO:0031295 9.26 LCK CTLA4 CD5 AKT1
17 T cell differentiation GO:0030217 8.92 PTPRC LCK KIT IL2

Molecular functions related to Thymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.23 TTN RYR1 PTPRC PPL NKX2-1 LRRC56
2 nucleotide binding GO:0000166 9.76 TTN RYR1 LCK KIT HRAS AKT3
3 kinase activity GO:0016301 9.43 TTN LCK KIT AKT3 AKT2 AKT1
4 protein kinase activity GO:0004672 9.1 TTN LCK KIT AKT3 AKT2 AKT1

Sources for Thymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....